Crescent Biopharma, Inc.
NASDAQ:CBIOBiotechnology
-$0.49 today
- Market cap
- $482.30M
- Beta
- 1.15
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$5.33
Volume 0.33M
Average 0.28M
CBIO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Crescent Biopharma, Inc.NASDAQ: CBIO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $4.11M rose 914.5% year over year, ahead of the +309.7% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 13.3% from the prior quarter. Over 3 fiscal years it compounded at +51.1% a year.
Context
- Stock-based compensation amounted to 122.6% of revenue in FY2025.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +914.5% holds above the trailing-twelve-month pace of +309.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 13.3M USD
- Year-over-year change
- +178.7%
- 4-year CAGR
- +21.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.3M | +178.7% |
| FY2024 | 2024-12-31 | 4.77M | +34.1% |
| FY2023 | 2023-12-31 | 3.56M | -7.7% |
| FY2022 | 2022-12-31 | 3.86M | -36.6% |
| FY2021 | 2021-12-31 | 6.09M | — |
Stock-Based Compensation vs competitors
How CBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +309.7% is the highest of 9, against a peer median of +9.2%.
- Stock-based compensation amounts to 136.2% of revenue for CBIO, versus a peer median of 20.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $63M USD | -6.0% | -2.6% | 53.8% | |
| LTM Sep 2026 | $37.94M USD | +56.7% | +91.1% | 14.3% | |
| LTM Sep 2026 | $36.81M USD | -0.7% | — | 32869.6% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥26.02M CNY | +1.1% | -74.4% | — |
| LTM Mar 2026 | $16.18M USD | +309.7% | +51.1% | 136.2% | |
| LTM Mar 2026 | $12.55M USD | -55.6% | -11.3% | 8.0% | |
| LTM Mar 2026 | $10.93M USD | +20.5% | +16.2% | — | |
| LTM Mar 2026 | $9.12M USD | +17.3% | -21.7% | 25.6% | |
| LTM Mar 2026 | $1.45M USD | +61.5% | +10.9% | — | |
| LTM Dec 2025 | $0 USD | — | — | 0.0% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CBIO) | — | +9.2% | -2.6% | 20.0% | |
Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (63.43M) | (46.69M) | (36.9M) | (37.88M) | (149.94M) |
| Depreciation & Amortization | 264.6K | 207.15K | 153.3K | 35.17K | 84K |
| Deferred Income Tax | 2.17K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.09M | 3.86M | 3.56M | 4.77M | 13.3M |
| Change in Working Capital | (1.17M) | (4.66M) | (2.56M) | 1.16M | (13.37M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | (18M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 17.68K | (1.14M) | (102.08K) | (538.81K) | 2.08M |
| Other Working Capital | (1.18M) | (3.52M) | (2.46M) | 1.7M | 2.55M |
| Other Non-Cash Items | 749.04K | 828.51K | 864.87K | 814.48K | 78.4M |
| Operating Cash Flow | (57.49M) | (46.46M) | (34.88M) | (31.1M) | (71.53M) |
| Capital Expenditures | (14.94K) | (84.19K) | (21.39K) | (9.97K) | (919K) |
| Acquisitions (Net) | 0 | 0 | 0 | 30K | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (72M) |
| Investing Cash Flow | (14.94K) | (84.19K) | (21.39K) | 20.03K | (72.92M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 10.7M | 4.16M | 28.71M | 5.4K | 5K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (177K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 25.03K | 0 | 116.5K | 0 | 323.16M |
| Financing Cash Flow | 10.72M | 4.16M | 28.82M | 5.4K | 322.98M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (46.78M) | (42.38M) | (6.08M) | (31.07M) | 178.53M |
| Free Cash Flow | (57.5M) | (46.54M) | (34.9M) | (31.11M) | (72.45M) |
Crescent Biopharma, Inc.
NASDAQ:CBIO
Intrinsic Alpha fair value
Locked
Current Price
$12.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.